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Antibody is an important antiviral defence. However, it is considered to do little against human
gamma-herpesviruses, which establish predominantly latent infections regulated by T cells. One
limitation on analysing these infections has been that latency is already well-established at clinical
presentation; early infection may still be accessible to antibody. Here, using murid herpesvirus-4
(MuHV-4), we tested the impact of adoptively transferred antibody on early gamma-herpesvirus
infection. Immune sera and neutralizing and non-neutralizing monoclonal antibodies (mAbs) all
reduced acute lytic MuHV-4 replication. The reductions, even by neutralizing mAbs, were largely
or completely dependent on host IgG Fc receptors. Therefore, passive antibody can blunt acute
gamma-herpesvirus lytic infection, and does this principally by IgG Fc-dependent functions rather
than by neutralization.
INTRODUCTION
Antibody provides an important defence against many
epidemic viruses. Its protective efficacy correlates with the
neutralization of cell-free virions (Zinkernagel &
Hengartner, 2006). This is reflected epidemiologically in
virus strains that differ mainly where neutralizing antibod-
ies bind. Whether antibody is also effective against
persistent pathogens such as gamma-herpesviruses is less
clear. The archetypal gamma-herpesvirus, Epstein–Barr
virus (EBV), causes disease mainly when latent; inhibiting
its lytic replication during acute infectious mononucleosis
makes little difference to latent viral loads (Yao et al.,
1989); also, long-term latent infection appears to be
controlled by T cells (Rickinson & Moss, 1997).
Therefore, antibody would seem to play little part in host
defence. However, EBV infection takes at least 1 month to
become symptomatic (Hoagland, 1964), by which time
latency is already well-established. The early events in
infection remain poorly defined. Substantial CD8
+ T-cell
responses to viral lytic antigens at clinical presentation
(Callan et al., 1996) suggest that significant lytic replication
occurs early on, and vaccination with a viral lytic antigen
can alleviate the symptoms of primary infection (Sokal et
al., 2007). Therefore, antibody might still be useful
therapeutically in acute settings such as organ transplanta-
tion into EBV-naive recipients, where primary EBV
infection confers a poor outcome (Walker et al., 1995).
Genetic immunodeficiencies can provide clues as to what
controls human viruses (Carneiro-Sampaio & Coutinho,
2007). However, B cell-deficient humans lack the main
EBV latency reservoir and consequently fail to support
normal persistence (Faulkner et al., 1999). The contri-
bution that antibody makes to host defence has therefore
been hard to define. The failure of EBV to establish a
significant experimental infection of non-primates further
limits the opportunities for direct analysis. We and others
(Virgin & Speck, 1999; Nash et al., 2001; Stevenson &
Efstathiou, 2005) have therefore developed murid herpes-
virus-4 (MuHV-4) as a small-animal model of gamma-
herpesvirus pathogenesis. MuHV-4 is genetically closer to
Kaposi’s sarcoma-associated herpesvirus than to EBV, but
its tropism and pathogenesis are similar to those of EBV,
and it currently provides the most tractable means to
establish how antibody might interact with a gamma-
herpesvirus in vivo.
T-cell depletion causes disease in B cell-deficient (Stewart
et al., 1998) but not immunocompetent (Stevenson et al.,
1999) MuHV-4 carriers, implying that antibody helps to
control established infection. In support of this idea,
adoptively transferred immune sera reduced MuHV-4
replication in B cell-deficient (Gangappa et al., 2002) and
T cell-depleted, CD28-deficient (Kim et al., 2002) mice,
and a rabbit serum raised against the MuHV-4 gp70
complement control protein reduced MuHV-4 replication
in B cell-deficient mice (Gangappa et al., 2002). However,
human gamma-herpesviruses cause disease more by latency-
associated tumours rather than by chronic lytic replication,
so the main opportunity for antibody to protect against
them is likely to be early on. The impact of antibody on early
MuHV-4 replication has not been tested.
The mechanism of antibody-mediated protection was not
addressed in the MuHV-4 studies listed above, but was
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2002) and correlated with in vitro virus neutralization in
the other (Gangappa et al., 2002). However, gamma-
herpesvirus neutralization is not well understood. For
example, EBV can be neutralized in vitro (Thorley-
Lawson & Geilinger, 1980), but EBV carriers continue to
transmit infection with little evidence of viral antigenic
variation, despite making virus-specific antibodies.
Immune sera can block MuHV-4 infection of fibroblasts
in vitro (Stevenson & Doherty, 1998), but they block in
vivo host entry poorly (Gillet et al., 2007a) and tend to
enhance MuHV-4 infection of IgG Fc receptor-positive
(FcR
+) cells such as macrophages (Rosa et al., 2007).
Thus, whilst immune sera can block virions binding to
fibroblasts (Gill et al., 2006), virion membrane fusion
seems to remain intact. Poor in vivo neutralization could
consequently reflect the availability of additional binding
routes that are harder for antibody to block. mAbs to
gH–gL and gB can block infection post-binding and
achieve a more universal neutralization (Gill et al., 2006;
Gillet et al., 2006), but gH–gL and gB are poorly
immunogenic, so this activity of immune sera is weak
(Gillet et al., 2007b). The virion fusion machinery – gH
and gB – is also protected by glycosylation (Gillet &
Stevenson, 2007a) and by gB and gH–gL associating on
the virion surface (Gillet & Stevenson, 2007a, b; Gillet et
al., 2009). The gB–gH–gL complex appears to unfold
only after a post-endocytic dissociation of gL (Gillet et
al., 2008a, b), so extracellular gB and gH can remain
protected. Another consideration is that in vivo gamma-
herpesvirus lytic spread may involve direct cell–cell
contact more than cell-free virion release, and thereby
resist neutralization as described for other herpesviruses
(Hooks et al., 1976).
We asked here whether immune sera or monoclonal
antibodies (mAbs) could reduce the primary lytic replica-
tion of MuHV-4 in immunocompetent hosts and, if so,
how they might act. Our aim was to define a basis for
antibody-based interventions in primary gamma-herpes-
virus infections.
METHODS
Mice. BALB/c, C57BL/6, 129Sv (Harlan UK) and 129Sv6B6 FcRc
2/2
FccRII
2/2 mice (Taconic Europe) were bred in the Cambridge
University Department of Pathology animal unit and infected with
MuHV-4 when 6–12 weeks old. Intranasal infections were performed
in a volume of 30 ml, given under general anaesthesia. For luciferase
imaging, mice were injected intraperitoneally with luciferin (2 mg per
mouse), anaesthetized with isoflurane, then scanned with an IVIS
Lumina (Caliper Life Sciences). Quantitative comparisons used the
total radiance (photons s
21 cm
22) over each region of interest,
relative to a negative-control region. All experiments conformed to
local animal-ethics regulations and to Home Office Project Licence
80/1992.
Sera and mAbs. Immune sera were collected at least 3 months post-
infection and pooled from 10–12 mice each. Hybridomas were
derived from MuHV-4-immune mice by fusion with NS0 myeloma
cells (Ko ¨hler & Milstein, 1975), except for mAb DW-6F6, which was
derived from mice infected with influenza A/PR/8/34 and is specific
for the influenza H1 haemagglutinin. Antibodies were concentrated
from hybridoma supernatants by ammonium sulfate precipitation,
dialysed against PBS, isotyped by ELISA (Sigma) and quantified by
Mancini assay (Mancini et al., 1965). Those used for in vivo
protection are listed in Table 1.
Cells and viruses. BHK-21 fibroblasts (ATCC CCL-10) and
NMuMG epithelial cells (CRL-1636) were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with 2 mM glutamine, 100 U
penicillin ml
21, 100 mg streptomycin ml
21 (all from Sigma) and 5%
fetal calf serum (PAA Laboratories). Hybridomas were grown in
RPMI medium (Sigma), supplemented as for DMEM. All viruses were
derived from a MuHV-4 bacterial artificial chromosome-cloned
genome (Adler et al., 2000). The wild type and its luciferase-
expressing derivative (Milho et al., 2009) were grown and titrated in
BHK-21 cells (de Lima et al., 2004). Infected cells were freeze–thawed
Table 1. Summary of mAbs used in vivo
Antibody Target Isotype Neutralization* In vivo titreD
LT-6E8 gp70 (SCR1+2) IgG2b 2 +
58-16D2 gp70 (SCR4) IgG2a 2 +
3F7 gN IgG2a 2 +
SC-9A5 gB IgG3 ++ ++
MG-2C10 gB IgM + 2
BN-3A4 gp150 IgG1 22
150-5A10 gp150 IgG2a 22
T7F5 gp150 IgG2a 22
T1A1 gp150 IgG2a 22
230-5B2 gH–gL IgG2a ++
T2C12 gH–gL IgG2a ++
230-4A2 gH–gL IgG2a ++
*Plaque reduction on BHK-21 cells, scored from negative (2) to strong (++).
DReduction in lung titre by plaque assay, scored from negative (2) to strong (++).
Anti-MuHV-4 antibody
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90 min). Cell debris was then removed by low-speed centrifugation
(1000 g, 10 min).
Virus titres and neutralization assays. MuHV-4 was titrated by
plaque assay on BHK-21 cells (de Lima et al., 2004). Infectious virus
in ex vivo tissues was measured by plaque assay of freeze–thawed
tissue homogenates. To determine virus titre in noses, we removed a
block of tissue bounded by the cartilaginous tip of the nose anteriorly,
the orbits posteriorly, the zygomatic arches laterally, the palate
ventrally and the nasal bones dorsally. Cell monolayers were
incubated with virus (2 h, 37 uC), overlaid with 0.3% carboxy-
methylcellulose and, 4 days later, fixed (4% formaldehyde) and
stained (0.1% toluidine blue) for plaque counting. Titres were
compared statistically between experimental groups by unpaired,
two-tailed t-tests, assuming equal variance. The calculations were
performed in Excel. P values of ,0.05 were considered statistically
significant.
Flow cytometry. MuHV-4-infected cells (2 p.f.u. per cell, 18 h) were
trypsinized, washed in PBS and incubated (1 h, 4 uC) with MuHV-4
glycoprotein-specific mAbs, followed by fluorescein-conjugated
rabbit anti-mouse IgG pAb (Dako Cytomation). The cells were
washed twice in PBS after each incubation and analysed on a
FACSCalibur (BD Biosciences).
Immunoblotting. N-Linked glycans were removed with protein N-
glycanase F; O-linked glycans were removed with sialidase A+O-
glycanase according to the manufacturer’s instructions (Prozyme).
Deglycosylated and intact samples were denatured (95 uC, 5 min) in
Laemmli’s buffer [60 mM Tris-Cl (pH 6.8); 3% (v/v) SDS; 5% (v/v)
2-mercaptoethanol; 10% (v/v) glycerol; 0.002% (v/v) bromophenol
blue], resolved by SDS-PAGE and transferred to PVDF membranes.
The membranes were blocked with 10% non-fat milk and probed
with MuHV-4-specific mAbs plus horseradish peroxidase-conju-
gated rabbit anti-mouse IgG pAb (Dako Cytomation). Membranes
were washed four times in PBS/0.1% Tween 20 after each step.
Bound antibody was visualized by ECL substrate development
(APBiotech).
RESULTS
Immune sera reduce MuHV-4 replication in naive
hosts
Adoptively transferred immune sera can reduce MuHV-4
replication in persistently infected mice that lack normal
antibody production (Gangappa et al., 2002; Kim et al.,
2002). We wanted to know whether immune sera could
also reduce acute viral replication in naive, immunocom-
petent hosts. We tested this by giving MuHV-4-immune
sera intraperitoneally to naive mice at the same time as
intranasal MuHV-4 virions (Fig. 1). Significant reductions
in virus titres were observed in both C57BL/6 (Fig. 1 a, b)
and BALB/c (Fig. 1c) mice and across multiple time points.
Naive sera had no effect (Fig. 1c).
We used luciferase-positive MuHV-4 (Milho et al., 2009)
as an alternative means of tracking in vivo lytic infection
(Fig. 2a, b). Immune sera again reduced significantly the
extent of acute host colonization. This was evident both in
lungs and in noses. Plaque assays (Fig. 2c) confirmed a
Fig. 1. Protection against MuHV-4 replication by immune sera. (a) C57BL/6 mice were given 310
4 p.f.u. MuHV-4 intranasally
(i.n.) and at the same time treated or not with 200 ml immune serum intraperitoneally (i.p.). Infectious virus in lungs was
measured by plaque assay 3 days later. Each point shows the titre for one mouse;  shows mean values. Immune serum
reduced lung titres significantly (P,0.0005 by two-tailed Student’s t-test). (b) C57BL/6 mice were infected and treated or not
with immune serum as in (a). The effects of immune serum on day 3 and day 6 titres were then compared. The reduction in titre
was significant at day 6 (P,0.0001), but not at day 3 (P50.06). (c) BALB/c mice were infected and given immune serum as in
(a), or naive serum as an additional control. Virus titres in lungs were determined after 5 days. Immune serum reduced titres
significantly compared with either virus only or naive serum (P,0.01). Naive serum had no effect compared with virus only
(P50.5).
D. E. Wright and others
2594 Journal of General Virology 90reduction in nose infection by immune serum. In other
experiments, we obtained similar data for noses and lungs,
but nose titres were generally more variable between
individual mice.
Non-neutralizing mAbs reduce MuHV-4
replication in naive hosts
Since the complexity of immune sera makes mechanisms of
protection difficult to establish, we used mAbs to explore
further the interaction between antibody and MuHV-4.
Table 1 summarizes the results. Fig. 3 shows neutralization
assays. In Fig. 4(a), mAb LT-6E8 reduced MuHV-4
replication compared with a control mAb (influenza
haemagglutinin-specific). LT-6E8 recognizes gp70, the
main product of MuHV-4 ORF4 (Gillet et al., 2007c)
and the target used by Gangappa et al. (2002) for
protection by immune serum. mAb 58-16D2, which
recognizes a different gp70 domain (Gillet et al., 2007c),
was also effective (Fig. 4b). As expected, neither LT-6E8
nor 58-16D2 affected the replication of MuHV-4 lacking
ORF4 (Fig. 4b).
The amounts of mAb used depended on what each
hybridoma produced. In general, we used the maximum
amount possible, so as not to miss a therapeutic effect. We
also ensured that at least 200 mg of any ineffective mAb was
given, so as to be sure that ineffectiveness did not reflect
Fig. 2. Immune serum limits MuHV-4 lytic gene expression in lungs and noses. (a) BALB/c mice were infected i.n. with
luciferase
+ MuHV-4 (310
4 p.f.u.) and at the same time given immune serum (200 ml), naive serum (200 ml) or nothing i.p.
Virus replication was monitored by luciferin injection and CCD camera scanning at 5 days post-infection. (b) Quantification of
signals shown in (a). Each point shows the luciferase signal of one mouse;  shows mean values. Immune serum reduced
luciferase expression significantly compared with naive serum (P,0.02 for noses, P,0.004 for lungs) or no-serum controls
(P,0.03 for noses, P,0.006 for lungs) using Student’s two-tailed t-test. (c) Noses from (a) were titrated for infectious virus by
plaque assay. Each point shows the titre for one mouse. Immune serum reduced titres significantly compared with naive serum
(P,0.005). Titres with immune serum were also lower than with virus only, although the wide scatter of values made this
difference non-significant by t-test (P50.06).
Anti-MuHV-4 antibody
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a standard effective mAb, showed that even 20 mg antibody
reduced MuHV-4 replication significantly.
LT-6E8 blocks heparan sulfate binding by gp70, but does
not neutralize (Fig. 3), because virions can also bind to
heparan sulfate via gH–gL. mAb 230-4A2 blocks heparan
sulfate binding by gH–gL and so neutralizes synergistically
with LT-6E8 (Gillet et al., 2008c). However, LT-6E8 and
230-4A2 gave no synergistic reduction in in vivo virus titres
(Fig. 4d). mAb MG-2C10 (Gillet et al., 2006), a
neutralizing, gB-specific IgM (Fig. 3), had no effect on in
vivo virus replication (Fig. 4e). mAbs 3F7 (gN-specific,
non-neutralizing) (May et al., 2005a) and SC-9A5 (gB-
specific, neutralizing) both reduced in vivo lytic replication,
whilst mAb BN-3A4 (gp150-specific, non-neutralizing) did
not (Fig. 4f). Therefore, no correlation, either positive or
negative, was evident between an antibody’s capacity to
neutralize cell-free virions in vitro and its capacity to
reduce virus replication in vivo.
Reduced lytic infection by antibody depends on
host IgG Fc receptors
The antiviral effect of IgG occurs principally by Fab-
dependent virion neutralization and by Fc-dependent
recruitment of other immune effectors. Recruiting cellular
effectors requires signalling through the common IgG Fc
receptor gamma chain (FcRc) (Nimmerjahn & Ravetch,
2008). We therefore explored the mechanism of antibody-
mediated protection by infecting FcRc
2/2 mice. We used
mice that also lacked the FcgRII inhibitory receptor
(FcRc
2/2FccRII
2/2), so as to reduce any excess immuno-
suppressive effect of IgG binding to cells lacking activating
Fc receptors. mAbs 3F7 and LT-6E8 both failed to reduce
virus titres significantly in the FcR
2 mice, whereas they
were effective in FcR
+ 129Sv controls (Fig. 5a). We
obtained an equivalent result (Fig. 5b) with C57BL/6
controls (the FcR
2 mice were 129Sv6C57BL/6) with mAb
58-16D2 (Fig. 5c), and with immune sera using both 129Sv
and C57BL/6 controls (Fig. 5c, d). Therefore protection by
both non-neutralizing mAbs and immune sera depended
on IgG Fc receptors.
Neutralization has at most a minor role in
antibody-mediated MuHV-4 control
As mAb SC-9A5 is an IgG3, it should not engage strongly
with IgG Fc receptors (Nimmerjahn & Ravetch, 2008).
Therefore, as a neutralizing mAb (Fig. 3), it might be
expected to reduce virus titres equally in FcR
2 and FcR
+
mice. In one experiment (Fig. 6a), SC-9A5 reduced the
virus titres of FcR
2 mice, but not to a significant level; in a
repeat experiment (Fig. 6b), the reduction was significant,
although there was also a significant reduction by mAb
3F7 (P,0.02), something not seen in other experiments
(e.g. Figs 5a, 6a). In both experiments, SC-9A5 gave a
substantially greater reduction in FcR
+ than FcR
2 mice
(4.6-fold rather than 1.9-fold in Fig. 6a; 17-fold rather than
3.7-fold in Fig. 6b).
We examined further a possible contribution of neutral-
ization to in vivo titre reductions with the gH–gL-specific
neutralizing mAbs T2C12 and 230-5B2 (Fig. 6c). Again,
there were substantial reductions in FcR
+ mouse titres,
and only small reductions that did not reach statistical
significance in FcR
2 mouse titres. Therefore, even
neutralizing mAbs acted in vivo largely through IgG Fc
receptor engagement.
gp150 is not an effective target for MuHV-4
control by mAbs
gp150 is expressed abundantly on MuHV-4-infected
fibroblasts and epithelial cells. Therefore, it was surprising
that the gp150-specific mAbs BN-3A4 (Fig. 4f), T7F5 (Fig.
6a) and 150-5A10 (Fig. 7a) all failed to reduce virus titres.
These mAbs all recognize epitopes contained within gp150
aa 108–151 (Gillet et al., 2007b). mAb T1A1, which
Fig. 3. In vitro neutralization of MuHV-4 virions by mAbs. MuHV-4
virions (100 p.f.u.) were incubated with mAbs and then plaque-
assayed on BHK-21 cells. The highest amounts of each antibody
used for neutralization correspond to the amounts given per
mouse. Small changes in infectivity (,3-fold reduction) were
considered not significant because of the potential for effects such
as virion cross-linking to operate in vitro. Thus, only mAbs MG-
2C10, T2C12, 230-5B2 and SC-9A5 were considered to be
neutralizing. Consistent results were obtained in at least two
experiments for each mAb.
D. E. Wright and others
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4( 3 10
4 p.f.u.) and at the same time given antibody i.p. (500 mg). Infectious virus titres in lungs were then determined by
plaque assay. Each point shows the titre for one mouse;  shows mean values. The gp70-specific mAb LT-6E8 reduced virus
titres significantly at day 5 (P,0.005 by Student’s two-tailed t-test) compared with the influenza haemagglutinin (flu HA)-
specific control, although not at day 3 (P50.1). (b) In an equivalent experiment, mAb LT-6E8 did not affect the replication of
gp70
” MuHV-4 (P50.2). mAb 58-16D2 (50 mg), which recognizes a different domain of gp70, also significantly reduced the
5 day post-infection titres of wild-type (wt; P,0.00002) but not gp70
” (P50.8) MuHV-4. (c) BALB/c mice were infected i.n.
with MuHV-4 (310
4 p.f.u.) and at the same time given mAb LT-6E8 i.p. in differing amounts. Infectious virus titres in lungs were
determined by plaque assay 5 days later. Each point shows the titre for one mouse;  shows mean values. All LT-6E8 amounts
reduced virus titres compared with the no-antibody control (P,0.003); 500 mg was marginally more effective than 56 or 19 mg
(P,0.04), but no more effective than 167 mg( P50.3). (d) BALB/c mice were infected i.n. with MuHV-4 (310
4 p.f.u.) and at
the same time given mAb LT-6E8 (500 mg) or mAb 230-4A2 (500 mg) i.p., both together or no antibody. Infectious virus titres in
lungs were determined by plaque assay 5 days later. All mAb treatments reduced virus titres significantly compared with the no-
antibody control (P,0.02). Both LT-6E8 and 230-4A2 together were more effective than LT-6E8 alone (P,0.03), but not more
effective than 230-4A2 alone (P50.8). (e) C57BL/6 mice were infected i.n. as in (a), and the effect of immune serum (200 ml)
was compared with that of the neutralizing gB-specific IgM mAb MG-2C10 (200 mg). Immune serum reduced virus titres
significantly (P,0.0001), whereas MG-2C10 had no effect (P50.7). (f) Mice were infected i.n. as in (a) and at the same time
given antibody or not i.p. (results of two separate experiments are shown). Infectious virus in lungs was titrated by plaque assay
5 days later. mAbs 3F7 (IgG2a, anti-gN, non-neutralizing, 40 mg) and SC-9A5 (IgG3, anti-gB, neutralizing, 500 mg) reduced
virus titres (P,0.002), whereas mAb BN-3A4 (IgG1, anti-gp150, non-neutralizing, 700 mg) did not (P50.9).
Anti-MuHV-4 antibody
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reduction (data not shown).
gp150 is predicted to be heavily O-glycosylated (Fig. 7b).
All of the gp150-specific mAbs used recognize glycan-
independent epitopes, as they recognize gp150 fragments
expressed in Escherichia coli (Gillet et al., 2007b and data
not shown), but glycans could potentially hide their
epitopes. We have found previously (Gillet & Stevenson,
2007a) that O-glycosylation inhibits gB recognition by
mAb MG-2C10. This manifests as virions from NMuMG
epithelial cells resisting recognition by MG-2C10 unless O-
Fig. 5. Antibody-mediated protection by non-neutralizing mAbs and by immune serum is IgG Fc receptor-dependent. (a)
FcRc
”/”FccRII
”/” mice (IgG FcR
”/”) were compared with 129Sv (IgG FcR
+/+) controls for antibody-dependent protection
against MuHV-4. Mice were infected i.n. (310
4 p.f.u.) and at the same time given antibody or not i.p. Infectious virus in lungs
was titrated 5 days later by plaque assay. Each point shows the titre for one mouse;  shows mean values. mAbs 3F7 (40 mg)
and LT-6E8 (500 mg) both reduced virus titres significantly in FcR
+/+ (P,0.02 by Student’s two-tailed t-test) but not FcR
”/”
(P50.3) mice. (b) IgG FcR
”/” or C57BL/6 (IgG FcR
+/+) mice were infected i.n. as in (a) and at the same time given i.p. 500 mg
LT-6E8 or DW-6F6 (anti-influenza haemagglutinin). Lungs were titrated for infectious virus 5 days later. mAb LT-6E8 reduced
titres significantly in IgG FcR
+/+ (P,0.05) but not IgG FcR
”/” (P50.5) mice compared with the control. (c) IgG FcR
”/” and
129Sv IgG FcR
+/+ mice were compared by lung virus titre 5 days after i.n. MuHV-4 infection and i.p. injection of either nothing
(virus only), immune serum (200 ml) or mAb 58-16D2 (50 mg). Immune serum reduced virus titres significantly in IgG FcR
+/+
(P,0.001) but not IgG FcR
”/” (P50.3) mice. mAb 58-16D2 also reduced virus titres significantly in IgG FcR
+/+ (P,0.02) but
not IgG FcR
”/” mice. (d) IgG FcR
”/” and C57BL/6 IgG FcR
+/+ mice were compared by lung virus titre 5 days after i.n. MuHV-4
infection and i.p. injection of either nothing (virus only) or immune serum (200 ml). Immune serum again reduced virus titres
significantly in IgG FcR
+/+ (P,0.0002) but not IgG FcR
”/” (P50.08) mice.
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fibroblasts are recognized with or without deglycosylation.
(Cells of epithelial origin presumably add more extensive,
mucin-like O-glycans.) Flow cytometry of MuHV-4-
infected NMuMG cells showed less staining than infected
BHK-21 cells for all gp150-specific mAbs (Fig. 7c). There
was also less gp150 detected by immunoblot of NMuMG
cell-derived compared with BHK-21 cell-derived virions
(Fig. 7d). The mAbs used recognize no products of the
corresponding gp150
2 or gp70
2 viruses; the bands below
70 kDa in Fig. 7(e) are all alternative glycoforms of gp70
(Gillet et al., 2007c). Reduced gp150 detection on NMuMG
cell-derived virions could reflect a lower gp150 content.
However, these virions do not show the typical gp150-
deficient phenotype (de Lima et al., 2004) of heparan
sulfate-independent infection (data not shown). Moreover,
Fig. 6. Antibody-mediated protection by neutralizing mAbs is also largely IgG Fc receptor-dependent. (a) C57BL/6 (IgG
FcR
+/+) or FcRc
”/”FccRII
”/” (IgG FcR
”/”) mice were infected with MuHV-4 i.n. (310
4 p.f.u.) and given antibody or not i.p.
Five days later, infectious virus in lungs was titrated by plaque assay. Each point shows the titre for one mouse;  shows mean
values. IgG FcR
+/+ mice showed a significant reduction in virus replication by mAbs SC-9A5 (500 mg) and 3F7 (40 mg)
(P,0.001 by Student’s two-tailed t-test), but not by mAb T7F5 (200 mg) (P50.2). None of the mAbs reduced virus replication
significantly in IgG FcR
”/” mice. (b) A repeat experiment again showed a significant reduction in IgG FcR
+/+ lung titres by
mAbs 3F7 (40 mg) and SC-9A5 (500 mg) (P,0.0003). This time the reduction in IgG FcR
”/” lung titres by SC-9A5, whilst
lower than that of IgG FcR
+/+ (3.7-fold rather than 17-fold), was also significant (P,0.0003), as was that by 3F7 (P,0.02).
(c) IgG FcR
+/+ and IgG FcR
”/” mice were further compared for virus titre reductions by the neutralizing gH–gL-specific mAbs
T2C12 (500 mg) and 230-5B2 (200 mg), using the same infection protocol as in (a). Both mAbs reduced lung virus titres
significantly in IgG FcR
+/+ (P,0.005) but not IgG FcR
”/” (P.0.13) mice.
Anti-MuHV-4 antibody
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by T1A1 was relatively preserved, whereas recognition by
T7F5 was reduced markedly. Therefore, it seemed more
likely that gp150 recognition was being masked.
gp150 has at least some some O-linked glycans, because it
is immunoprecipitated readily by jacalin (May et al.,
2005b). Removing O-linked glycans did not increase
convincingly the detection of NMuMG-cell-derived
gp150 (Fig. 7e). However, the detection of BHK-21 cell-
derived gp150 decreased markedly, presumably because
gp150 became unstable (or was otherwise lost) when its O-
linked glycans were removed. (Note that the actual
molecular mass of gp150 is very difficult to infer from
SDS-PAGE: O-glycan digestion retards its migration even
further.) The greater equivalence of NMuMG and BHK-21
Fig. 7. O-Glycosylation may make gp150 a poor therapeutic antibody target. (a) C57BL/6 (IgG FcR
+/+) or FcRc
”/”FccRII
”/”
(IgG FcR
”/”) mice were infected i.n. with MuHV-4 (310
4 p.f.u.) and given antibody or not i.p. Five days later, infectious virus in
lungs was titrated by plaque assay. Each point shows the titre for one mouse;  shows mean values. IgG FcR
+/+ mice showed
a significant reduction in virus replication by mAb LT-6E8 (500 mg) (P,0.002), but not by mAb 150-5A10 (200 mg) (P50.9),
using Student’s two-tailed t-test. Neither mAb reduced virus replication significantly in IgG FcR
”/” mice. (b) Predicted O-
glycosylation sites in gp150 (Julenius et al., 2005). The predicted signal sequence (residues 1–22) and transmembrane domain
(residues 459–481) are also shown. (c) Flow-cytometric analysis of BHK-21 cells (solid lines) and NMuMG cells (dashed lines)
infected with MuHV-4 (2 p.f.u. per cell, 18 h). Control5secondary antibody only. mAbs 8C1 (anti-gH) and BN-1A7 (anti-gB)
provide controls for the level of infection. None of the mAbs stained uninfected cells. Staining with mAb 150-5A10 was
equivalent to that of BN-3A4. (d) Immunoblot of virions derived from NMuMG cells (NMu) or BHK-21 cells (BHK). Each blot
shows two independently grown virus stocks from each cell type. mAb 150-7D1 recognizes the ORF17 capsid component and
provides a loading control. (e) Virions derived from NMuMG cells or BHK-21 cells were untreated (nil), digested with PNGase F
to remove N-linked glycans (N”) or digested with sialidase+O-glycanase to remove O-linked glycans (O”). Samples were
then immunoblotted for gp150. mAb 150-7D1 (ORF17) provides a loading control; mAb 58-16D2 demonstrates O-linked
glycan removal from gp70 in the same samples.
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glycosylation substantially modified recognition by gp150-
specific mAbs. Therefore, differential glycosylation could
explain the inefficacy of gp150-specific mAbs in reducing
in vivo virus titres.
DISCUSSION
Passive antibody, given promptly, attenuates primary alpha-
herpesvirus infections (Whitley, 1994; Ogilvie, 1998).
Gamma-herpesviruses are generally viewed as less accessible
to antibody-based interventions, as they colonize their hosts
largely by latency-associated lymphoproliferation. We show
here that immune sera and mAbs can nonetheless reduce
MuHV-4 acute lytic replication and that they act predomi-
nantly by IgG Fc receptor engagement.
Antibody can protect mice against herpes simplex virus
(HSV) both by neutralization and by IgG Fc receptor-
dependent functions (McKendall, 1985; Ishizaka et al.,
1995). Early studies mainly compared neutralizing and
non-neutralizing mAbs. Whilst antibodies capable of
neutralization need not act by neutralization, the finding
that glycoprotein C was a viable target for antibody in vivo
and not for neutralization (Balachandran et al., 1982;
Ku ¨mel et al., 1985) argued that, here at least, protection
involved host Fc receptors. Protection by immune serum
was subsequently shown to be IgG Fc receptor-dependent
(Chu et al., 2008). The difficulty with interpreting such
results is that the HSV gE–gI binds human but not mouse
IgG Fc (Johansson et al., 1985). In contrast, MuHV-4
naturally infects mice (Kozuch et al., 1993) and gamma-
herpesviruses are not known to express IgG Fc receptors.
Our findings with MuHV-4 – i.e. that non-neutralization
epitopes provided effective antibody targets in vivo and
that protection by immune serum was largely IgG Fc
receptor-dependent – therefore suggested that antibodies
generally act via Fc receptors in host defence against
herpesviruses.
One difference between MuHV-4 and HSV is that the HSV
gD provides a good neutralization target (Minson et al.,
1986); the analogous (although non-homologous) MuHV-
4 gp150 does not, and seems to function instead in
antibody evasion. gp150 is abundant on infected-cell
surfaces, but gp150-specific mAbs failed to reduce in vivo
virus replication. Some uncertainty remains over gp150
processing: the equivalent gene of most other gamma-
herpesviruses can be spliced (Beisel et al., 1985) to exclude
some of the region equivalent to the immunogenic ‘stalk’
of gp150 (Gillet et al., 2007b). However, we have found no
evidence of gp150 splicing by RT-PCR, either in vitro or in
vivo (data not shown). A mAb recognizing the C-terminal
part of the gp150 extracellular domain identifies additional,
faster-migrating forms on SDS-PAGE, suggesting the
possibility of post-translational cleavage (data not shown),
but we have not detected corresponding N-terminal
fragments in infected-cell supernatants, so these may
simply be different glycoforms. Also, gp150 cleavage alone
would not explain gp150-specific mAbs being ineffective,
as gp70 is shed abundantly into infected-cell supernatants
(Kapadia et al., 1999; Gillet et al., 2007c) yet remained a
good antibody target. Differential gp150 glycosylation
seems more likely to limit the impact of gp150-specific
mAbs.
The importance of IgG Fc receptors in limiting in vivo
MuHV-4 replication was consistent with MuHV-4 neut-
ralization being much more difficult than in vitro assays of
fibroblast infection would suggest (Gillet et al., 2007a). One
consideration is virions blocked for fibroblast infection by
immune sera using IgG Fc receptors to productively infect
myeloid cells (Smith et al., 2007). However, there was no
evidence for neutralization being more effective in FcRc
2/2
than in FcRc
+/+ mice. Therefore, a more important
consideration is probably the in vivo accessibility of virions
to antibody. gp48, which promotes direct MuHV-4 cell–
cell spread via actin polymerization (Gill et al., 2008),
contributes more to in vivo virus replication (May et al.,
2005c) than does gp150, which functions in virion release
(de Lima et al., 2004), or gL, which functions in virion cell
binding (Gillet et al., 2007d). Similarly, HSV cell–cell
spread via gE contributes significantly to dissemination in
vivo but not in vitro (Dingwell et al., 1994), whilst cell
binding by gp50 is important for pseudorabies virus
dissemination in vitro, yet is largely dispensable in vivo
(Peeters et al., 1993). Thus, herpesviruses seem generally to
remain cell-associated in vivo, affording limited opportun-
ities for neutralization. As the main function of cell-free
virions is genome transmission between hosts, their release
need not extend beyond apical epithelial cells. The
difficulty of herpesvirus neutralization may limit what
passive antibody can achieve – certainly the inhibition of
MuHV-4 replication achieved here was relatively modest.
Further study is required to determine whether this reflects
a specific mechanism of viral evasion.
Which IgG Fc receptor-dependent effector mechanism
limits MuHV-4 replication remains unclear. Antibody-
dependent cytotoxicity seems the most likely. Depleting
natural killer (NK) cells with mAb PK136 (anti-NK1.1) had
no effect on antibody-mediated protection (data not
shown). However, macrophages, monocytes or granulo-
cytes may be more important mediators of such cytotoxi-
city in mice (Nimmerjahn & Ravetch, 2008). Another
(non-exclusive) possibility is enhanced virion uptake by
dendritic cells improving T-cell priming. Thus, the failure
of gp150-specific antibodies to reduce viral titres could
have reflected that their opsonization allows particularly
efficient dendritic-cell infection after uptake, and therefore
disruption of antigen presentation (Smith et al., 2007;
Gillet et al., 2007b), as opposed to virion uptake without
infection, which should allow efficient antigen presenta-
tion. The in vivo fate of opsonized virions and infected cells
clearly requires further study. The present data indicate
that it is this, rather than neutralization, that chiefly
determines the therapeutic effect of antiviral antibodies.
Anti-MuHV-4 antibody
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Whilst unlikely to prevent infection, it could potentially be
helpful acutely in immunosuppressed patients exposed to
EBV by reducing the extent of lytic viral spread. Antibody
might also be a useful adjunct to latency-directed therapies
such as adoptive T-cell transfer. Most considerations of
anti-EBV antibody have focused on gp350 because anti-
gp350 mAbs can block B-cell infection in vitro (Thorley-
Lawson & Geilinger, 1980). The ineffectiveness of mAbs
against the MuHV-4 gp150 suggested that other targets
might be better in vivo.
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